Literature DB >> 33629336

COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.

S A Meo1, I A Bukhari, J Akram, A S Meo, D C Klonoff.   

Abstract

OBJECTIVE: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses. The US Food and Drug Administration, (FDA) has granted emergency use authorization for treatment with the Pfizer/BioNTech and Moderna COVID-19 vaccines. Many people have a history of a significant allergic reaction to a specific food, medicine, or vaccine; hence, people all over the world have great concerns about these two authorized vaccines. This article compares the pharmacology, indications, contraindications, and adverse effects of the Pfizer/BioNTech and Moderna vaccines.
MATERIALS AND METHODS: The required documents and information were collected from the relevant databases, including Web of Science (Clarivate Analytics), PubMed, EMBASE, World Health Organization (WHO), Food and Drug Authorities (FDA) USA, Local Ministries, Health Institutes, and Google Scholar. The key terms used were: Coronavirus, SARS-COV-2, COVID-19 pandemic, vaccines, Pfizer/BioNTech vaccine, Moderna vaccine, pharmacology, benefits, allergic responses, indications, contraindications, and adverse effects. The descriptive information was recorded, and we eventually included 12 documents including research articles, clinical trials, and websites to record the required information.
RESULTS: Based on the currently available literature, both vaccines are beneficial to provide immunity against SARS-CoV-2 infection. Pfizer/BioNTech Vaccine has been recommended to people 16 years of age and older, with a dose of 30 μg (0.3 m) at a cost of $19.50. It provides immunogenicity for at least 119 days after the first vaccination and is 95% effective in preventing the SARS-COV-2 infection. However, Moderna Vaccine has been recommended to people 18 years of age and older, with a dose of 50 μg (0.5 mL) at a cost of $32-37. It provides immunogenicity for at least 119 days after the first vaccination and is 94.5% effective in preventing the SARS-CoV-2 infection. However, some associated allergic symptoms have been reported for both vaccines. The COVID-19 vaccines can cause mild adverse effects after the first or second doses, including pain, redness or swelling at the site of vaccine shot, fever, fatigue, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain, and can also rarely cause anaphylactic shock. The occurrence of adverse effects is reported to be lower in the Pfizer/BioNTech vaccine compared to the Moderna vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.
CONCLUSIONS: The FDA has granted emergency use authorization for the Pfizer/BioNTech and Moderna COVID-19 vaccines. These vaccines can protect recipients from a SARS-CoV- 2 infection by formation of antibodies and provide immunity against a SARS-CoV-2 infection. Both vaccines can cause various adverse effects, but these reactions are reported to be less frequent in the Pfizer/BioNTech vaccine compared to the Moderna COVID-19 vaccine; however, the Moderna vaccine compared to the Pfizer vaccine is easier to transport and store because it is less temperature sensitive.

Entities:  

Year:  2021        PMID: 33629336     DOI: 10.26355/eurrev_202102_24877

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  144 in total

Review 1.  A narrative review of emergency use authorization versus full FDA approval and its effect on COVID-19 vaccination hesitancy.

Authors:  Thoyaja Koritala; Akbar Hussain; Yelena Pleshkova; Lavanya Dondapati; Raghavendra Tirupathi; Ali A Rabaan; Abbas Al Mutair; Saad Alhumaid; Jaffar A Al-Tawfiq; Rahul Kashyap
Journal:  Infez Med       Date:  2021-09-10

Review 2.  Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.

Authors:  Ramesh Kandimalla; Pratik Chakraborty; Jayalakshmi Vallamkondu; Anupama Chaudhary; Sonalinandini Samanta; P Hemachandra Reddy; Vincenzo De Feo; Saikat Dewanjee
Journal:  Biomedicines       Date:  2021-11-22

3.  Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China.

Authors:  Guangfei Wang; Lin Zhu; Yiqing Zhu; Qiaofeng Ye; Xin Yu; Meng Fu; Jinmiao Lu; Xiaoxia Li; Yidie Huang; Junqi Zhang; Jianger Lan; Ziwei Li; Xiaowen Zhai; Hong Xu; Zhiping Li
Journal:  Hum Vaccin Immunother       Date:  2021-04-22       Impact factor: 3.452

4.  Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination.

Authors:  Abdulla Watad; Gabriele De Marco; Hussein Mahajna; Amit Druyan; Mailam Eltity; Nizar Hijazi; Amir Haddad; Muna Elias; Devy Zisman; Mohammad E Naffaa; Michal Brodavka; Yael Cohen; Arsalan Abu-Much; Muhanad Abu Elhija; Charlie Bridgewood; Pnina Langevitz; Joanna McLorinan; Nicola Luigi Bragazzi; Helena Marzo-Ortega; Merav Lidar; Cassandra Calabrese; Leonard Calabrese; Edward Vital; Yehuda Shoenfeld; Howard Amital; Dennis McGonagle
Journal:  Vaccines (Basel)       Date:  2021-04-29

5.  In Silico Investigation of Phytoconstituents of Medicinal Herb 'Piper Longum' Against SARS-CoV-2 by Molecular Docking and Molecular Dynamics Analysis.

Authors:  Shradha Lakhera; Kamal Devlal; Arabinda Ghosh; Meenakshi Rana
Journal:  Results Chem       Date:  2021-09-24

6.  The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19.

Authors:  Izabela Jęśkowiak; Benita Wiatrak; Patrycja Grosman-Dziewiszek; Adam Szeląg
Journal:  Vaccines (Basel)       Date:  2021-05-13

7.  Immune Response to COVID-19 mRNA Vaccine-A Pilot Study.

Authors:  Andrzej Lange; Agata Borowik; Jolanta Bocheńska; Joanna Rossowska; Emilia Jaskuła
Journal:  Vaccines (Basel)       Date:  2021-05-11

8.  Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.

Authors:  Alberto Modenese; Stefania Paduano; Annalisa Bargellini; Rossana Bellucci; Simona Marchetti; Fulvio Bruno; Pietro Grazioli; Roberto Vivoli; Fabriziomaria Gobba
Journal:  Vaccines (Basel)       Date:  2021-06-15

9.  COVID‑19 vaccination and IgG and IgA antibody dynamics in healthcare workers.

Authors:  Sabina Zurac; Luciana Nichita; Bogdan Mateescu; Cristian Mogodici; Alexandra Bastian; Cristiana Popp; Mirela Cioplea; Claudiu Socoliu; Carolina Constantin; Monica Neagu
Journal:  Mol Med Rep       Date:  2021-06-16       Impact factor: 2.952

10.  Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines.

Authors:  Chris Painter; Wanrudee Isaranuwatchai; Juthamas Prawjaeng; Hwee Lin Wee; Brandon Wen Bing Chua; Vinh Anh Huynh; Jing Lou; Fang Ting Goh; Nantasit Luangasanatip; Wirichada Pan-Ngum; Wang Yi; Hannah Clapham; Yot Teerawattananon
Journal:  Appl Health Econ Health Policy       Date:  2021-07-08       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.